Leap therapeutics presents dkn-01 clinical data at the society of gynecologic oncology 2021 annual meeting on women's cancer

Cambridge, mass., march 22, 2021 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of clinical data from its phase 2 clinical trial of dkn-01 as a monotherapy and in combination with paclitaxel in patients with advanced gynecological malignancies at the society of gynecologic oncology 2021 annual meeting on women's cancer, being held as a virtual meeting from march 19-25, 2021.
LPTX Ratings Summary
LPTX Quant Ranking